More Stories

Informist, Friday, Aug. 07, 2026

 

MUMBAI – The Nifty Pharma index is expected to rise next week, supported by factors ranging from defensive buying to strong domestic performance in the June quarter. While stocks of US-focused companies may remain under selling pressure, contract development and manufacturing companies are expected to have upside potential and will likely rise more next week. Contract manufacturing companies have reported strong growth in the June quarter, which is not a seasonally strong quarter. Relative immunity from US President Donald Trump's threat to impose large tariffs on generic products is also playing in their favour.

 

This week, the Nifty Pharma index ended almost flat from last week at 26541.80 points. Contract development and manufacturing organisations had a great run this week, with shares of Piramal Pharma, Gland Pharma, and Sai Life Sciences ending 4-7% higher. With Wockhardt and Laurus Labs yet to report their June quarter earnings, analysts said CDMO stocks could see a positive ripple effect if these companies post strong earnings. Torrent Pharmaceuticals, Alkem Laboratories, and Sun Pharmaceutical Industries ended 2–4% lower and were a major drag on the Nifty Pharma index. 

 

Lupin's shares will likely be under pressure in the near term after the company's management signalled a strong decline in quarterly revenues from the US in upcoming quarters. Despite higher-than-expected revenues for the June quarter, the company's shares ended almost 1% lower Friday, primarily due to subpar US sales growth. The company expects to take the bulk of the price erosion impact on Tolvaptan and mirabegron generics in the coming quarters. Its management said Lupin will likely report quarterly revenue ranging between $250 million and $280 million from the US for the next few quarters, significantly lower than its June quarter revenue of $366 million.

 

The Nifty Pharma index is moving upward in a higher-highs and higher-lows formation above its key long-term as well as short-term moving averages, Vipin Kumar, assistant vice president – research at Globe Capital Market said. "Considering its current chart structure, we suggest that traders continue with a buy-on-dips trading approach as long as the index holds above the 25400 spot level on a closing basis," he said. A dip from the 26000–25800 spot zone should be taken as a fresh buying opportunity, Kumar suggested. He expects the index to face resistance at 26800–27200 levels and find support around 26150–25800 points.

 

TOP HEADLINES

 

* Earnings Review: Lupin Q1 PAT boosted by US, India sales despite high costs
* Sai Life Sciences Apr-Jun consol PAT rises 21% on year, revenue rises 12%
* US FDA issues warning letter to Dabur over issues at co's Silvassa plant
* US FDA issues 7 observations to Alkem Lab manufacturing unit in Daman
* Biocon says competition unlikely to hit biosimilar sales at least for 5 yrs
* Emcure Pharma Apr-Jun consol PAT rises 42% YoY to INR 2.94 billion
* Analyst Concall: Biocon sees new launches driving FY27 growth, margins
* Analyst Concall: Aurobindo Pharma expects arm Eugia FY27 revenue at $500 mln
* Earnings Outlook: Higher competition, tax to limit Lupin's PAT rise in Q1
* Earnings Review: Neuland Lab's net profit up nearly 11 times YoY on low base
* Earnings Review:Aurobindo Pharma Q1 PAT beats view; sales, other income jump
* Earnings Review: Biopharma ops lift Biocon Apr-Jun consol revenue by 10% YoY
* US FDA issues 5 observations to Cohance Life's mfg unit in Hyderabad
* Gland Pharma, Neuland Labs partner for sterile API manufacturing
* Cohance Life posts INR 241.2 million consol loss in Apr-Jun vs PAT yr ago
* HC notice to patent dept, Novastis AG on Natco Pharma plea on  Ribociclib
* Dabur says removing '100%' claims from labels after food regulator's notice
* Analyst Concall: Alembic Pharma sees US sales better than expected FY27
* Zydus Life gets US FDA nod for Indocyanine Green to tap $125.8-mln market
* Sudeep Pharma Apr-Jun consol PAT rises 32% YoY to INR 405.5 million
* Earnings Review: Alembic Pharma Q1 PAT, revenue beat Street estimates
* Dr Reddy's launches generic Sugammadex in US to tap $1.6 bln market
* Earnings Outlook: Biosimilars to lead Biocon's Q1 consol PAT growth YoY
* US FDA issues establishment inspection report to Cipla US arm's unit
* Earnings Outlook: Europe to drive Aurobindo Pharma Q1 consol PAT growth
* Analyst Concall: Torrent Power invests INR 23 bln capex in Apr-Jun
* Earnings Review: GSK Pharma Q1 PAT up 16% on year, slightly above view
* Dr Reddy's registers drug for rare head, neck cancer in South Africa
* IPO Alert: Encube Ethicals files DRHP for INR-30-bln IPO; issue entirely OFS
* Piramal Pharma resumes operations at Sanand facility after heavy rainfall
* Earnings Review: Blue Jet Health Q1 PAT, revenue down YoY
* Biocon announces commercial launch of biosimilar Yesafili in US market
* SPOTLIGHT: Indian pharma sector in wait-and-watch mode on Trump tariff plan
* Analyst Concall:Glenmark Pharma sees high double-digit growth in Europe FY28
* Earnings Outlook: GSK Pharma Q1 net seen up on price hikes, new launches
* Analyst Concall: Divi's Lab to keep 3 mos' inventory to tackle supply blips
* US FDA tags Zydus Life Ahmedabad unit 'voluntary action indicated'
* Earnings Review: Divi's Lab Q1 PAT up 60% YoY, much higher than estimates
* Neuland Lab starts production at additional capacities in Telangana units
* Dr Reddy's gets US FDA approval for Rituximab biosimilar
* US FDA approves Lupin's anxiety drug Diazepam, sales value seen at $78 mln
* Earnings Review: Glenmark Pharma Q1 PAT jumps over 10-fold on low base
* Aarti Drugs Apr-Jun consol PAT falls 6.9% YoY to INR 501.7 million
* Analyst Concall: Sun Pharma says on track to meet FY27 R&D spend aim
* Concord Biotech Apr-Jun consol PAT rises 32.8% YoY to INR 585.26 million
* HC bars Torrent Pharma from launching drug with Novartis-patent Dabrafenib
* Earnings Review: Sun Pharma Q1 earnings miss estimates on Revlimid drag

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	27835.00	0.10	28178.30	27428.30
Alkem Laboratories	5620.00	(-)2.30	5732.70	5449.70
Aurobindo Pharma	1658.00	4.90	1715.90	1550.90
Biocon	426.35	0.20	440.20	418.40
Cipla	1463.80	(-)0.60	1482.50	1452.70
Divi's Laboratories	8275.00	2.70	8381.30	8180.30
Dr Reddy's Laboratories	1172.00	2.10	1178.60	1158.80
Gland Pharma	2601.00	3.90	2646.90	2547.10
GlaxoSmithKline Pharmaceuticals	2599.70	(-)2.10	2662.10	2525.30
Glenmark Pharmaceuticals	2279.10	2.00	2307.70	2241.70
Granules India	873.85	6.00	909.00	821.80
Ipca Laboratories	1735.80	(-)0.70	1764.10	1697.50
Laurus Labs	1844.30	1.60	1867.30	1821.70
Lupin	2363.50	(-)2.10	2437.20	2309.20
Natco Pharma	916.65	(-)0.00	923.90	907.40
Pfizer	4880.60	1.20	4960.20	4810.20
Sanofi India	3349.40	1.00	3373.50	3308.10
Sun Pharmaceutical Industries	1945.00	(-)2.30	1974.30	1910.50
Torrent Pharmaceuticals	4924.00	(-)3.90	5024.00	4851.00
Zydus Lifesciences	1114.20	(-)1.10	1132.90	1083.90
Index	Levels
Nifty Pharma	26541.80	0.00	26677.90	26336.40
Nifty 50	24570.65	0.80	24682.30	24467.00
S&P Bse Sensex	78499.17	0.50	78924.90	78164.20

 

 

End

 

US$1 = INR 95.21

 

Reported by Eshitva Prakash

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.